Acute Limb Ischaemia (ALI) Management With 'Indigo' Mechanical Aspiration System

Sponsor
Lancashire Care NHS Foundation Trust (Other)
Overall Status
Unknown status
CT.gov ID
NCT03295539
Collaborator
St. Franziskus Hospital (Other)
400
1
1
15.9
25.1

Study Details

Study Description

Brief Summary

International Multi-Centre registry recording comprehensive data on the use of 'Indigo' Mechanical thrombectomy system by Penumbra Inc for the removal of acute clot causing acute or critical limb ischaemia.

Condition or Disease Intervention/Treatment Phase
  • Device: 'Indigo' Mechanical thrombectomy system
N/A

Detailed Description

A detailed registry has been designed and approved to be used world wide in vascular and trauma centres, already providing endovascular service for the management of critical limb ischaemia (CLI).

Recent campaigns have shown little is done to improve flow to the lower limbs (legs) of patients to avoid amputation rates. During this time many devises have been used and available on the market. The 'Indigo' system by Penumbra was originally designed from the acute stroke system "ACE". Similar principles were applied in designing the 'Indigo' system. This is currently being used in many centres to manage acute clot causing lower limb ischaemia, however no official registry or international clinical trial has been done to show its significance in managing this disease.

The investigator groups, have created this to come up with enough data to evaluate the Indigo system in the management of (ALI) and offer tips and tricks to other clinicians. The aim is for a single arm, multicenter, retrospective analysis of patients in whom (ALI) was performed with the Penumbra/Indigo System (study device), and gather greater data and information than the PRISM trial in 2013-2014 which obtained only 79 patients.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
MulticentRe pOst-market exPeriencE With the INdigo Thrombectomy System for the Treatment of Acute Lower Limb Ischaemia : (Re-Open Registry)
Anticipated Study Start Date :
Nov 1, 2017
Anticipated Primary Completion Date :
Oct 1, 2018
Anticipated Study Completion Date :
Mar 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Other: Acute or Chronic clot

If chronic clot, no intervention given via Indigo

Device: 'Indigo' Mechanical thrombectomy system
Removal of acute clot from the artery causing ischaemia, using the mechanical aspiration system by Penumbra Inc called "INDIGO"

Outcome Measures

Primary Outcome Measures

  1. Technical success using the Indigo system. [Time to event anaylsis. Primary patency results are immediate after the case on the final angiogram images.]

    Intraoperative technical success defined as the restoration of antegrade blood flow with complete or near complete (95% by volume) removal of the thrombus or embolus (70% threshold). This is assessed using imaging modalities (USS/Doppler/Fluroscopy) and clinical assessment of the affected limb. See for this definition the enclosed citation. In conclusion, the primary outcome measure will be improvement in blood flow across a lesion assessed by the improvement in Thrombolysis in Myocardial Infarction (TIMI) score that was adapted to peripheral arteries. Concomitant balloon angioplasty or stent placement in addition to VAT was considered a complementary treatment. Additional thrombectomy treatments, such as thrombolysis and mechanical thrombectomy, were considered technical failures.Target lesions were grouped anatomically into above-the-knee(ATK) or below-the-knee(BTK) lesions.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Acute lower limb Ischaemia with acute soft clot.
Exclusion Criteria:
  • Calcified plaques/ chronic disease causing critical limb Ischaemia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Interventional Radiology Preston Lancashire United Kingdom PR2 7HR

Sponsors and Collaborators

  • Lancashire Care NHS Foundation Trust
  • St. Franziskus Hospital

Investigators

  • Study Chair: Bella Huasen, MD, Lancashire NHS

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Bella Huasen, Endovascular Interventional Consultant, Lancashire Care NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT03295539
Other Study ID Numbers:
  • Indigo2017
First Posted:
Sep 28, 2017
Last Update Posted:
Oct 20, 2017
Last Verified:
Oct 1, 2017
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 20, 2017